Sun Pharmaceutical Industries Ltd. has announced a major expansion move, with its wholly-owned subsidiary Sun Pharma Laboratories receiving board approval for a ₹3,000 crore investment to establish a new greenfield formulations manufacturing plant in Madhya Pradesh. The update was confirmed through a regulatory filing on Monday, highlighting the company’s continued commitment to strengthening domestic production capabilities.
In addition to the investment announcement, Sun Pharma also introduced its globally recognized biologic drug, Ilumya (Tildrakizumab), to the Indian market. The treatment—targeted at patients with moderate-to-severe plaque psoriasis—has already gained strong clinical acceptance internationally and is praised for its long-term safety and efficacy profile.
The company’s leadership remains optimistic about growth momentum. In a recent interview with CNBC-TV18, Chief Financial Officer Jayashree Satagopan said that Sun Pharma expects its India business to outperform the broader pharmaceutical market, supported by strategic brand investments and focus on high-potential therapeutic categories.
Sun Pharma’s latest quarterly results reflect this trajectory, with the drugmaker posting stronger-than-estimated profits driven by double-digit domestic market performance and solid demand across key segments.
Summary
- Sun Pharma will invest ₹3,000 crore via its subsidiary to build a new greenfield formulations plant in Madhya Pradesh.
- The company has launched Ilumya (Tildrakizumab) in India, an innovative biologic therapy for plaque psoriasis already established globally.
- Sun Pharma expects continued above-market growth in India, supported by brand strength and therapy focus.
- The company reported better-than-expected quarterly earnings, powered by domestic demand and growth across core therapeutic areas.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.